UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR Delaware 47-5195942 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...

PRAXIS O CORPORATE OVERVIEW May 2023 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________ Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (St ...

PRAXIS 0 CORPORATE OVERVIEW November 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical resul ...

PRAXIS 0 CORPORATE OVERVIEW August 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results ...

PRAXIS ● CORPORATE OVERVIEW May 2022 Forward-looking statements 2 This presentation may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, operations, and financial conditions, including but not limited to express or implied statements regarding the current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results an ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Marcio Souza – President and Chief executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President Investor Relations and Corporate Communications Conference Call Participants Lauren Riaz – Piper Sandler Laura Chico – Wedbush Securities Yasmeen Rahimi – Piper Sandler Ritu Baral – Cowen & Company Myles Minter – William Blair Douglas Tsao – H.C. Wainwright Operat ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q4 2021 Earnings Conference Call February 28, 2022 8:30 AM ET Company Participants Marcio Souza – President and Chief Executive Officer Bernard Ravina – Chief Medical Officer Alex Kane – Vice President of Investor Relations and Corporate Communications Conference Call Participants Yasmeen Rahimi – Piper Sandler Laura Chico – Wedbush Securities Ritu Baral – Cowen & Company Tazeen Ahmad – Bank of America Merrill Lynch Myles Minter – William Blair Douglas Tsao – H ...